Predicting circulating biomarker response and its impact on the survival of advanced melanoma patients treated with adjuvant therapy.
Itziar Irurzun-AranaEduardo Asin-PrietoSalvador Martín-AlgarraIñaki F TrocónizPublished in: Scientific reports (2020)
Advanced melanoma remains a disease with poor prognosis. Several serologic markers have been investigated to help monitoring and prognostication, but to date only lactate dehydrogenase (LDH) has been validated as a standard prognostic factor biomarker for this disease by the American Joint Committee on Cancer. In this work, we built a semi-mechanistic model to explore the relationship between the time course of several circulating biomarkers and overall or progression free survival in advanced melanoma patients treated with adjuvant high-dose interferon-[Formula: see text]. Additionally, due to the adverse interferon tolerability, a semi-mechanistic model describing the side effects of the treatment in the absolute neutrophil counts is proposed in order to simultaneously analyze the benefits and toxic effects of this treatment. The results of our analysis suggest that the relative change from baseline of LDH was the most significant predictor of the overall survival of the patients. Unfortunately, there was no significant difference in the proportion of patients with elevated serum biomarkers between the patients who recurred and those who remained free of disease. Still, we believe that the modelling framework presented in this work of circulating biomarkers and adverse effects could constitute an additional strategy for disease monitoring in advance melanoma patients.
Keyphrases
- prognostic factors
- poor prognosis
- free survival
- high dose
- ejection fraction
- newly diagnosed
- long non coding rna
- dendritic cells
- squamous cell carcinoma
- emergency department
- low dose
- early stage
- skin cancer
- patient reported outcomes
- open label
- stem cell transplantation
- high resolution
- young adults
- papillary thyroid
- basal cell carcinoma
- coronavirus disease
- electronic health record
- respiratory syndrome coronavirus